Chiral Aryl Propionic Acid Derivative Selection for Joint Distribution
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing loxoprofen sodium formulations are marketed in a racemic form with no distinction in pharmacological effects among its chiral isomers, and there is a need for a more effective, non-steroidal anti-inflammatory drug with better joint distribution and reduced adverse reactions.
Innovation Solution
Development of a chiral aryl propionic acid derivative with specific structural modifications to enhance anti-inflammatory and analgesic effects, allowing for better joint fluid distribution and reduced dosage requirements.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If loxoprofen sodium is marketed in a racemic form, then manufacturing simplicity is maintained, but pharmacological effectiveness and joint distribution are insufficient
Solution Approach 1:
The racemic mixture of loxoprofen is separated into individual chiral isomers (R-isomer, S-isomer, and diastereoisomers), allowing each isomer to be evaluated and selected for optimal pharmacological activity. This segmentation enables identification of the most effective isomer while maintaining manufacturing feasibility through established chiral separation techniques.
2Reliability
If structural modifications are made to enhance anti-inflammatory effects, then therapeutic efficacy is improved, but molecular complexity increases
Solution Approach 1:
Specific structural modifications are introduced at targeted positions on the loxoprofen molecule (such as substituent groups at defined locations in the general formula) to enhance anti-inflammatory activity and joint distribution. These localized modifications improve therapeutic efficacy while maintaining overall molecular simplicity and manufacturability.
Data Source
AI summary
A chiral aryl propionic acid derivative and a pharmaceutical composition thereof, and a use. The chiral aryl propionic acid derivative is as shown in formula (I). The chiral aryl propionic acid derivative has antipyretic, analgesic and anti-inflammatory effects. The compound has high activity and can be locally administrated, a reduced dosage is expected, and adverse reactions are reduced.